Humana Faces Investor Lawsuit Over Alleged Misleading Utilization Costs

U.S. District Judge Jennifer L. Hall ruled on April 27, 2026, that key claims against Humana’s former CEO and CFO will advance to trial. The litigation centers on allegations that between July 2022 and October 2024, the company downplayed its exposure to post-pandemic medical utilization expenses. The court found that the plaintiffs sufficiently alleged the defendants acted with scienter—an intent to defraud—when making statements that kept stock prices artificially high.

As the reality of the company's financial position surfaced in June 2023, Humana reported disappointing results, triggering a sharp decline in share value. During the period when the allegedly misleading statements were made, corporate insiders offloaded more than $104 million in company stock. Law firm Schubert Jonckheer & Kolbe LLP is now investigating potential legal claims against the company’s directors and officers, encouraging current shareholders to review their options as the litigation moves forward.